Company: DMAC
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001437749-25-034469
Chunk: 6

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part II, Item 1A
Chunk 6
---
1      Certification of Chief Executive Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                         Filed herewith                                                                                                                                                   
     31.2      Certification of Chief Financial Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                         Filed herewith                                                                                                                                                   
     32.1      Certification of Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                       Furnished herewith                                                                                                                                               
     32.2      Certification of Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                       Furnished herewith                                                                                                                                               
      104      Cover Page Interactive Data File                                                                                                                                                                          Embedded within the Inline XBRL document                                                                                                                         

* Certain exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K. A copy of any omitted exhibit can be furnished to the Commission upon its request*

+ Certain personal information, which would constitute an unwarranted invasion of personal privacy, has been redacted from this exhibit pursuant to Item 601 of Regulation S-K.

# Management contract or compensation plan or arrangement

23

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                               DIAMEDICA THERAPEUTICS INC.                                     
  Date: November 12, 2025      /s/ Rick Pauls                                                  
                               Rick Pauls                                                      
                               (Principal Executive Officer)                                   
  Date: November 12, 2025      /s/ Scott Kellen                                                
                               Scott Kellen                                                    
                               (Principal Financial Officer and Principal Accounting Officer)  

24